spacer gif spacer gif spacer gif spacer gif Propose a workshop for 2011 spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    


This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribatti, D.
Right arrow Articles by Presta, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribatti, D.
Right arrow Articles by Presta, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Cell Science, Vol 112, Issue 23 4213-4221, Copyright © 1999 by Company of Biologists


JOURNAL ARTICLES

In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2

D Ribatti, D Leali, A Vacca, R Giuliani, A Gualandris, L Roncali, ML Nolli and M Presta
Institute of Human Anatomy, University of Bari, Piazza G. Cesare 11, Italy.

In vitro experimental evidences suggest that the proteolytic degradation of the extracellular matrix (ECM) by activation of the urokinase-type plasminogen activator (uPA)/plasmin system may affect growth factor activity and bioavailability. However, no direct in vivo observations were available to support this hypothesis. Here we demonstrate that endothelial GM 7373 cells overexpressing human uPA (uPA-R5 cells) cause the release of (125)I-labeled fibroblast growth factor-2 (FGF2) from endothelial ECM in a plasmin-dependent manner. Accordingly, uPA-R5 cells are angiogenic in vivo when applied on the top of the chorioallantoic membrane (CAM) of the chick embryo. In contrast, mock-transfected Neo2 cells are unable to release ECM-bound (125)I-FGF2 and are poorly angiogenic. Neovascularization elicited by uPA-R5 cells is significantly reduced by neutralizing anti-FGF2 antibodies to values similar to those observed in Neo2 cell-treated CAMs. Accordingly, purified human uPA stimulates neovascularization of the CAM in the absence of an inflammatory response. The angiogenic activity of uPA is significantly inhibited by neutralizing anti-FGF2 antibodies or by pretreatment with phenylmethylsulfonyl fluoride. The non-catalytic, receptor-binding amino-terminal fragment of uPA is instead non angiogenic. Taken together, the data indicate that uPA is able to induce angiogenesis in vivo via a plasmin-dependent degradation of ECM that causes the mobilization of stored endogenous FGF2.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
V. C. Ardi, P. E. Van den Steen, G. Opdenakker, B. Schweighofer, E. I. Deryugina, and J. P. Quigley
Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway
J. Biol. Chem., September 18, 2009; 284(38): 25854 - 25866.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
H. W. Smith, P. Marra, and C. J. Marshall
uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180
J. Cell Biol., August 25, 2008; 182(4): 777 - 790.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. Lamagna, M. Aurrand-Lions, and B. A. Imhof
Dual role of macrophages in tumor growth and angiogenesis
J. Leukoc. Biol., October 1, 2006; 80(4): 705 - 713.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax
Pericellular Proteases in Angiogenesis and Vasculogenesis
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 716 - 728.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Margosio, D. Marchetti, V. Vergani, R. Giavazzi, M. Rusnati, M. Presta, and G. Taraboletti
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2
Blood, December 15, 2003; 102(13): 4399 - 4406.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. R. Harvey, T. C. Hurd, G. Markus, M. I. Martinick, R. M. Penetrante, D. Tan, P. Venkataraman, N. DeSouza, S. N. J. Sait, D. L. Driscoll, et al.
Evaluation of Urinary Plasminogen Activator, Its Receptor, Matrix Metalloproteinase-9, and von Willebrand Factor in Pancreatic Cancer
Clin. Cancer Res., October 15, 2003; 9(13): 4935 - 4943.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
S. Stefansson and D. A. Lawrence
Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration
Sci. Signal., July 1, 2003; 2003(189): pe24 - pe24.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. A. Hardikar, B. Marcus-Samuels, E. Geras-Raaka, B. M. Raaka, and M. C. Gershengorn
Human pancreatic precursor cells secrete FGF2 to stimulate clustering into hormone-expressing islet-like cell aggregates
PNAS, June 10, 2003; 100(12): 7117 - 7122.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Pepper
Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis
Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1104 - 1117.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta
Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors
Cancer Res., January 1, 2001; 61(1): 309 - 317.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
T. L. Frandsen, C. Holst-Hansen, B. S. Nielsen, I. J. Christensen, J. R. Nyengaard, P. Carmeliet, and N. Brünner
Direct Evidence of the Importance of Stromal Urokinase Plasminogen Activator (uPA) in the Growth of an Experimental Human Breast Cancer Using a Combined uPA Gene-Disrupted and Immunodeficient Xenograft Model
Cancer Res., January 1, 2001; 61(2): 532 - 537.
[Abstract] [Full Text]




© The Company of Biologists Ltd 1999